EUCTR2022-003786-38-IT招募中1 期
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors - FAPI Basket
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 个研究点目标入组 50 人开始时间: 2022年11月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Patients must have histologically or cytologically solid tumors at any stage
- •2.18F-FDG PET/CT scan dubious or inconclusive
- •3.Male or Female, aged>18 years
- •4.ECOG performance status <2
- •5.If female of childbearing potential highly effective birth control methods, according to guideline Recommendation related to contraception and pregnancy testing in clinical trials”, (2014_09_15 section 4.1) are mandatory. Highly effective birth control methods are required beginning at the screening visit and continuing at least 6 months following last treatment with study drug. Negative serum pregnancy test for females of childbearing potential within 14 days of starting treatment. Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 6 months after final study drug administration. Two acceptable methods of birth control thus include Condom (barrier method of contraception) and one of the following is required ( established use of oral, or injected or implanted hormonal method of contraception by the female partner; placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner; additional barrier method like occlusive cap with spermicidal foam/gel/film/cream/suppository in the female partner; tubal ligation in the female partner; vasectomy or other procedure resulting in infertility (eg., bilateral orchiectomy), for more than 6 months.
- •6.Participant is willing and able to give informed consent for participation in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1.Participation in another clinical trial with any investigational agents within 30 days prior to study entry.
- •2.Medical or psychological conditions that would not allow the participant to understand, or sign the informed consent
- •3.History of allergic reactions attributed to compounds of similar chemical or biologic composition to FAPI or other agents used in the study.
- •4.Inability to remain still for the entire duration of the exam
- •5.Pregnancy and lactation
研究者
相似试验
招募中
1 期
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)CTIS2024-511659-17-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.100
进行中（未招募）
1 期
68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical TrialEUCTR2021-000148-23-DEniversity Hospital Essen155
进行中（未招募）
1 期
PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis.Progressive Pulmonary Fibrosis (PPF)MedDRA version: 21.0Level: PTClassification code: 10037383Term: Pulmonary fibrosis Class: 100000004855CTIS2023-503686-26-00St Antonius Hospital20
招募中
1 期
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian CancerMedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Ovarian CancerCTIS2023-505938-98-00Aalborg University Hospital50
招募中
1 期
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging after Chemotherapy in Patients with Gastric and Gastro-Esophageal Junctional CancerCTIS2023-505916-40-01Aalborg University Hospital20